



**Novartis India Limited**  
Registered Office:  
Inspire BKC  
Part of 601 & 701  
Bandra Kurla Complex  
Bandra (East)  
Mumbai – 400 051  
Maharashtra, India  
Tel +91 22 50243000  
Fax +91 22 50243010  
Email: india.investors@novartis.com  
CIN No. L24200MH1947PLC006104  
Website: www.novartis.in

June 2, 2022

The Secretary  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Scrip Code: 500672

Dear Sir/ Madam,

**Sub.: Disclosure of Related Party Transactions for the half year ended March 31, 2022 under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')**

Pursuant to Regulation 23(9) of the SEBI Listing Regulations, please find enclosed herewith the disclosure of Related Party Transactions on standalone basis for the half year ended March 31, 2022.

This is for your information and records.

Thanking you

Yours sincerely,

For Novartis India Limited

*Nikhil Malpani*



**Nikhil Malpani**  
Company Secretary and Compliance Officer

**Novartis India Limited**

**Related Party Disclosures for half year Ended 31st March 2022**

**(A) Enterprise where control exists**

Holding Company and Ultimate Holding Company                      Novartis AG, Switzerland

**(B) Other Related Parties with whom the company had transactions during the year and/or the previous year**

- (i) Fellow Subsidiaries      Novartis Asia Pacific Pharmaceutical Pte Ltd, Singapore  
    Novartis Healthcare Private Limited, India  
    Novartis Holding AG, Switzerland  
    Novartis Pharma Services AG, Switzerland  
    Novartis Pharma AG, Switzerland  
    Sandoz Private Limited, India
- (ii) List of other related parties (Post-employment benefit plan of Novartis India Limited)  
    Novartis India Limited Employees' Provident Fund  
    Novartis India Limited Superannuation Fund

**(C) Key Management Personnel**

S. Murdeshwar  
 C. Snook  
 J. Hiremath @  
 S. Martyres @  
 Sanker Parmeswaran @  
 Monaz Noble\*

@ Independent Directors

\* Non Independent Non Executive Director

**(D) Disclosure of transactions between the company and related parties and outstanding balances as at the year end:**

**Half year ended 31st March, 2022**  
**in ₹ million**

**(a) Holding Company and Ultimate Holding Company**

Royalty Expense	15.3
Balance as at the year end - Outstanding Payable	17.4

**(b) Fellow Subsidiaries**

**Half year ended 31st March, 2022**  
**in ₹ million**

Purchases of Stock-in-Trade Novartis Pharma AG	479.8
	479.8
Sale of Services Novartis Healthcare Private Limited Sandoz Private Limited	33.3
	1.7
	35.0
Commission Income Novartis Healthcare Private Limited	56.4
	56.4
Facility Usage charges recovery Novartis Healthcare Private Limited	18.2
	18.2
Services Availed Novartis Healthcare Private Limited Novartis Pharma AG	19.2
	0.6
	19.8
Sale of Fixed assets Novartis Healthcare Private Limited	40.0
	40.0



**Novartis India Limited**

Purchase of Restricted Shares of Novartis AG on behalf of employees of the Company by

Novartis Holding AG	11.2
	<u>11.2</u>

Expenses paid by Company on behalf of the related party

Novartis Pharma Services AG	29.7
	<u>29.7</u>

31st March, 2022

in ₹ million

Balances as at the year end -

Outstanding Receivables

Novartis Healthcare Private Limited	97.8
Novartis Pharma AG	38.6
Novartis Pharma Services AG	9.3
	<u>145.7</u>

Outstanding Payables

Novartis Healthcare Private Limited	68.7
Novartis Holding AG	11.2
Novartis Pharma AG	230.7
	<u>310.6</u>

**(c) Post Employment Benefit Plans of Novartis India Limited**

Half year ended 31st March, 2022

in ₹ million

Novartis India Limited Employees' Superannuation Fund	0.3
	<u>0.3</u>

Balances as at the year end -

Advances to

Novartis India Limited Employees' Provident Fund	3.0
	<u>3.0</u>

**(d) Key Management Personnel Compensation**

Half year ended 31st March, 2022

in ₹ million

Short-term employee benefits	7.2
Commission to Independent Directors	2.8
Sitting fees to Independent Directors	1.4
<b>Total compensation</b>	<u>11.4</u>

Notes:

1) No amounts have been written off/provided for or written back in respect of amounts receivable from or payable to the related parties except as disclosed above.

2) Outstanding balances at the year-end are unsecured and interest free and settlement occurs in cash.

